Thomas E. Polen Jr.
Net Worth
Last updated:
What is Thomas E. Polen Jr. net worth?
The estimated net worth of Mr. Thomas E. Polen Jr. is at least $96,460,364 as of 15 Aug 2022. He owns shares worth $5,719,288 as insider, has earned $16,941,076 from insider trading and has received compensation worth at least $73,800,000 in Becton, Dickinson and Company and Becton, Dickinson and Company.
What is the salary of Thomas E. Polen Jr.?
Mr. Thomas E. Polen Jr. salary is $3,690,000 per year as Pres, Chief Executive Officer & Chairman in Becton, Dickinson and Company. He also receives $3,690,000 as Pres, Chief Executive Officer & Chairman in Becton, Dickinson and Company.
How old is Thomas E. Polen Jr.?
Mr. Thomas E. Polen Jr. is 52 years old, born in 1973.
What stocks does Thomas E. Polen Jr. currently own?
As insider, Mr. Thomas E. Polen Jr. owns shares in 2 companies:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Becton, Dickinson and Company (BDX) | Pres, Chief Executive Officer & Chairman | 28,878 | $198.05 | $5,719,288 |
| Becton, Dickinson and Company (BDXB) | Pres, Chief Executive Officer & Chairman | 28,878 | $0 | $0 |
What does Becton, Dickinson and Company do?
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
What does Becton, Dickinson and Company do?
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Thomas E. Polen Jr. insider trading
Becton, Dickinson and Company
Mr. Thomas E. Polen Jr. has made 10 insider trades between 2015-2022, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 15,000 units of BDX stock on 15 Aug 2022. As of 15 Aug 2022 he still owns at least 28,878 units of BDX stock.
Becton, Dickinson and Company
Mr. Thomas E. Polen Jr. has made 10 insider trades between 2015-2022, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 15,000 units of BDXB stock on 15 Aug 2022. As of 15 Aug 2022 he still owns at least 28,878 units of BDXB stock.
Becton, Dickinson and Company key executives
Becton, Dickinson and Company executives and other stock owners filed with the SEC:
- Mr. Alberto Mas (64) Executive Vice President & Pres of the Medical Segment
- Mr. Christopher DelOrefice (54) Executive Vice President & Chief Financial Officer
- Mr. Samrat S. Khichi Esq. (58) Executive Vice President of Corporation Devel., Public Policy & Regulatory Affairs and Gen. Counsel
- Mr. Simon D. Campion (54) Executive Vice President & Pres of Interventional Segment
- Mr. Thomas E. Polen Jr. (52) Pres, Chief Executive Officer & Chairman